[Development of early diagnosis of Parkinson's disease based on the search for biomarkers such as premotor symptoms and changes in blood].

Autor:	Gusev EI; Pirogov Russian National Research Medical University, Moscow, Russia., Katunina EA; Pirogov Russian National Research Medical University, Moscow, Russia.; Federal Center for Brain and Neurotechnologies, Moscow, Russia., Martinov MY; Pirogov Russian National Research Medical University, Moscow, Russia., Blokhin VE; Koltsov Institute of Developmental Biology RAS, Moscow, Russia., Kalinkin AL; Medical Research and Education Center of Lomonosov Moscow State University, Moscow, Russia., Alesenko AV; Emanuel Institute of Biochemical Physics RAS, Moscow, Russia., Nodel MR; Sechenov First Moscow State Medical University, Moscow, Russia., Malykhina EA; Pirogov Russian National Research Medical University, Moscow, Russia.; Federal Center for Brain and Neurotechnologies, Moscow, Russia., Titova NV; Pirogov Russian National Research Medical University, Moscow, Russia.; Federal Center for Brain and Neurotechnologies, Moscow, Russia., Katunin DA; Pirogov Russian National Research Medical University, Moscow, Russia.; Federal Center for Brain and Neurotechnologies, Moscow, Russia., Shupik MA; Emanuel Institute of Biochemical Physics RAS, Moscow, Russia., Gutner UA; Emanuel Institute of Biochemical Physics RAS, Moscow, Russia., Maloshitskaya OA; Lomonosov Moscow State University, Moscow, Russia., Sokolov SA; Lomonosov Moscow State University, Moscow, Russia., Kucheryanu VG; Institute of General Pathology and Pathophysiology, Moscow, Russia., Pavlova EN; Koltsov Institute of Developmental Biology RAS, Moscow, Russia., Ugrumov MV; Koltsov Institute of Developmental Biology RAS, Moscow, Russia.
Jazyk:	ruština
Zdroj:	Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2020; Vol. 120 (12), pp. 7-17.
DOI:	10.17116/jnevro20201201217
Abstrakt:	Objective: To determine changes in the chemical composition of blood plasma in subjects at risk of Parkinson's disease (PD) at the prodromal stage compared with age control. Material and Methods: Subjects at risk were selected for the presence of characteristic premotor symptoms, including impairments of sleep, olfaction and constipation.The risk group included 12 people, the control group - 8 people. Results: Among seven catecholamines and their metabolites detected in the blood, only the concentration of L-dioxiphenylalanine (L-DOPA) changed (decreased) in subjects at risk compared with the control. A decrease in the concentration of L-DOPA is considered as a manifestation (marker) of selective degeneration of central and peripheral catecholaminergic neurons in PD. In contrast to L-DOPA, the concentration of seven of the twelve detected sphingomyelins in the blood of the subjects at risk increased. Given that a change in the metabolism of sphingomyelins is associated with processes such as apoptosis, autophagy, and synucleinopathy, an increase in their concentration in the blood of patients at risk is considered as a manifestation of systemic general degeneration of central and peripheral neurons. Finally, in the blood of subjects at risk, we found a trend towards a decrease in the concentration of urates, which are endogenous neuroprotectors. Conclusion: The changes in the level of L-DOPA, sphingmyelins and urates in the blood of subjects at risk may serve as diagnostic markers of PD at the prodromal stage.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu